Systematic Review of Efficacy and Health Economic Implications of Real-world Treatment Sequencing in Prostate Cancer: Where Do the Newer Agents Enzalutamide and Abiraterone Fit in?
Amanda Pereira-Salgado, Edmond Michael Kwan, Ben Tran, Peter Gibbs, Johann De Bono, Maarten IJzerman
EUROPEAN UROLOGY FOCUS | ELSEVIER | Published : 2021
CONTEXT: Optimal treatment sequencing of abiraterone and enzalutamide in chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) is challenging. Real-world data (RWD) allow a better understanding of health economic implications in the real world. OBJECTIVE: To determine survival and cost outcomes for two real-world treatment sequences, comparing abiraterone to enzalutamide (AA → ENZ) with enzalutamide to abiraterone (ENZ → AA). EVIDENCE ACQUISITION: A systematic review was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement. Searches were performed in Medline, Embase, and Web of Science. EVIDENCE SYNTHESIS: Seven..View full abstract
Amanda Pereira-Salgado certifies that all conflicts of interest, including specific financial interests and relationships and affiliations relevant to the subject matter or materials discussed in the manuscript (eg, employment/affiliation, grants or funding, consultancies, honoraria, stock ownership or options, expert testimony, royalties, or patents filed, received, or pending) , are the following: Edwond Kwan: honoraria-Janssen; research funding-Astellas Pharma and AstraZeneca; travel/accommodation-Astellas Pharma, Pfizer, and Ipsen. Ben Tran: hon-oraria: speaker, advisory, and travel-Amgen and Astellas; advisory and travel-Bayer and Sanofi; speaker and advisory-BMS and Janssen-Cilag; advisory-MSD, Novartis, Tolmar, and Ipsen; research funding: registry (to Walter and Eliza Hall Institute, WEHI) -Amgen, Astellas,Janssen-Cilag, and Pfizer; registry translational research (to WEHI) -Astra Zeneca; data report (to WEHI) -Bayer and Ipsen; registry data report (to WEHI) -BMS; clinical trials to Peter MacCallum Cancer Centre-Serier. Professor Johann de Bono reports personal fees and nonfinancial support from Astellas Pharma and Sanofi; grants, personal fees, and nonfinancial support from AstraZeneca; personal fees from Genentech/Roche, Pfizer, Bayer, Boehringer Ingelheim, Merck Serono, and Merck Sharp & Dohme; nonfinancial support from Genmab, GlaxoSmithKline, Orion Pharma GmbH, Qiagen, Taiho Pharma-ceutical, and Vertex, outside the submitted work. In addition, Professor de Bono has a patent Abiraterone Rewards to Inventors with royalties paid to institution, no personal income, and a patent PARP inhibitors and DNA repair defects with royalties paid to institution, no personal income.